LAKE FOREST, Ill., May 17, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that Ajay Patel, Chief Financial Officer, will host investor meetings as part of the Benchmark & Company Healthcare House Call Virtual Conference, taking place May 21-22, 2024. Investors participating in the Benchmark conference can request a meeting via their ...

LAKE FOREST, Ill., May 17, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that Ajay Patel, Chief Financial Officer, will host investor meetings as part of the Benchmark & Company Healthcare House Call Virtual Conference, taking place May 21-22, 2024. Investors participating in the Benchmark conference can request a meeting via their ...

Letter Expresses Several Significant Concerns and Recommends That Further Investigation is WarrantedUrges Assertio Stockholders to Vote Against All Directors at Upcoming Annual Meeting in Order to Either Pressure Current Board to Accept New Stockholder-Recommended Directors or Force Resignations of Significant Portion of Board Pursuant to BylawsNEW YORK, May 17, 2024 /PRNewswire/ -- The Buxton Helmsley Group, Inc. (together with certain of its affiliates, "BHG" or "we"), a New York City-based investment fun ...

LAKE FOREST, Ill., May 16, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that Ajay Patel, Chief Financial Officer, will present at the Alliance Global Partners Virtual Healthcare Company Showcase to be held virtually on May 21, 2024. Mr. Patel will present an overview of Assertio's business at 3:40 p.m. Eastern Time. The event is ho ...

LAKE FOREST, Ill., May 16, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that Ajay Patel, Chief Financial Officer, will present at the Alliance Global Partners Virtual Healthcare Company Showcase to be held virtually on May 21, 2024. Mr. Patel will present an overview of Assertio’s business at 3:40 p.m. Eastern Time. The event is h ...

Urges Assertio Stockholders to Vote Against All Directors at Upcoming Annual Meeting in Order to Either Pressure Current Board to Accept New Stockholder-Recommended Directors or Force Resignations of Significant Portion of Board Pursuant to Bylaws Board and Management Inappropriately Answered or Refused to Answer Questions Over Very Material Matters Believes Insiders May Have Not Personally Purchased Shares in Over Three Years Due to Material Non-Public Information Last Remaining Investor-Minded Advocate o ...

LAKE FOREST, Ill., May 10, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. ("Assertio" or the "Company") (NASDAQ:ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that Ajay Patel, Chief Financial Officer, will present at the Citizens JMP Life Sciences Conference to be held May 13, 2024 in New York City. The Company will host a group presentation at 12:00 pm Eastern Time, and be available for individual meetings throughou ...

LAKE FOREST, Ill., May 10, 2024 (GLOBE NEWSWIRE) -- Assertio Holdings, Inc. (“Assertio” or the “Company”) (Nasdaq: ASRT), a pharmaceutical company with comprehensive commercial capabilities offering differentiated products to patients, today announced that Ajay Patel, Chief Financial Officer, will present at the Citizens JMP Life Sciences Conference to be held May 13, 2024 in New York City. The Company will host a group presentation at 12:00 pm Eastern Time, and be available for individual meetings througho ...

财务数据和关键指标变化 - 第一季度总销售额为31.9百万美元,较上一季度32.5百万美元略有下降 [15] - Rolvedon销售额为14.5百万美元,较上一季度11百万美元增长32%,主要由于销量增加 [16] - Indocin销售额为8.7百万美元,较上一季度10.8百万美元下降,主要由于受到仿制药竞争的影响 [17] - 剔除存货增值影响,第一季度毛利率为78%,较上一季度79%略有下降 [17] 各条业务线数据和关键指标变化 - Rolvedon连续第5个季度实现需求增长,这是该产品的关键成功指标 [9] - Rolvedon在公司目前服务的门诊Medicare Part B市场的份额约为34% [28] - 公司正在通过进一步渗透新的医疗机构以及增加现有医疗机构的销量来推动Rolvedon的增长 [29][30] - Indocin目前仍有一家仿制药竞争,公司份额约为50%,正在努力维护市场份额和价格竞争力 [31] - Sympazan的表现符合预期,公司正在进行增量战略投资以提高市场知名度和销量增长 [32][33] 各个市场数据和关键指标变化 - Rolvedon在公司目前服务的门诊Medicare Part B市场的份额约为34% [28] - 公司正在通过进一步渗透新的医疗机构以及增加现有医疗机构的销量来推动Rolvedon的增长 [29][30] 公司战略和发展方向及行业竞争 - 公司正在努力通过增加销售和盈利能力、多元化收入来源以及产生更可预测的现金流来实现可持续的长期股东价值 [12] - 公司正在寻找可以增加销售和盈利能力、提高业务持续性和可预测性的投资机会 [23] - 公司正在评估通过直销还是更多数字互动的销售模式来引入新产品 [38][39] - 公司正在广泛寻找新产品,不局限于肿瘤支持治疗领域,但也希望能找到更好地利用现有资产的产品 [40][41] 管理层对经营环境和未来前景的评论 - 公司正在执行良好,第一季度业绩符合全年指引 [9] - 公司正在努力维护Indocin的市场份额和价值,同时推动Rolvedon的增长 [31] - 公司正在进行战略投资以提高Sympazan的市场知名度和销量增长 [32][33] - 公司正在积极寻找新的增长机会和现金流资产 [23][38][39][40][41] 问答环节重要的提问和回答 问题1 **Jim Sidoti 提问** 关于Rolvedon同日给药试验的时间线和潜在影响 [36] **Paul Schwichtenberg 回答** 试验数据预计在第四季度公布,但不会带来标签变更,对2024年影响有限 [37] 问题2 **Thomas Flaten 提问** 关于Sympazan的增量战略投资计划 [47] **Paul Schwichtenberg 回答** 公司正在调整营销组合,以提高对医生和患者的覆盖,预计2025年才会看到影响 [48][49] 问题3 **Thomas Flaten 提问** 关于未来毛利率水平的预期 [52] **Ajay Patel 回答** 随着Indocin业务下降,预计毛利率将稳定在中70%左右 [53]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NUMBER 001-39294 ASSERTIO HOLDINGS, INC. (EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER) Delaware 85-0598378 (STATE OR OTHER JURISDICTION OF (I ...